The Medicare Report Card That Decides This Stock's Next Move

30‑Second Take

Why now? Cantor Fitzgerald upgraded Humana to Overweight from Neutral on October 7 and lifted its price target to $460 from $300. The firm cited growing confidence in Humana's Medicare Advantage margins and a recovery in its quality ratings.

Those ratings are the swing factor. Medicare's 2027 Star Ratings were scheduled to come out on or about October 8, and they set the bonus payments Humana collects in 2028. Management has said it expects to return to top-quartile results.

The stock popped toward $410 on the upgrade, then slipped about 2% by the close as the broader market sold off. It's up roughly 50% this year but still sits a bit below its 52-week high near $429.

Trade Setup

Timeframe: 6 to 12 months

Edge type: Ratings recovery plus an earnings rebound priced off a trough year

This is not a beaten-down value play anymore. The easy money off the lows is gone, and you're paying for a recovery that still has to show up in the numbers.

What you're buying is the bridge from a weak 2026 to a much stronger 2027 and 2028. If the new Star Ratings confirm the turnaround, the Street's earnings estimates have room to keep climbing.

Snapshot Table

Chart

1-Month Trading Summary: HUM is roughly flat over the past month, down about 2%, after a strong summer run. It's up about 50% year to date and sits roughly 7% below its 52-week high.

The stock has spent the last few weeks chopping in a range as investors wait on two events: the Star Ratings release and third-quarter results on Friday, November 6.

Bull Case 

Why It Works

Star Ratings drive real money in Medicare Advantage. Plans rated 4 stars or higher earn bonus payments, and Humana lost a big chunk of those after its 2025 ratings slipped. That's the main reason management expects 2026 earnings to fall from last year.

The flip side is the setup for 2028. If the 2027 ratings come back to where Humana says they should, those bonus dollars return, and the earnings jump that follows is what Cantor is betting on.

The Catalysts

The first catalyst is the Star Ratings themselves. If they're already out when you read this, check one thing before you act: how much of Humana's membership landed in plans rated 4 stars or higher.

The second is growth. Humana added roughly 1 million Medicare Advantage members during the last enrollment period. It now covers about 7 million enrollees, around 20% of the market, according to KFF.

The third is the November 6 earnings report. In July, Humana affirmed its 2026 adjusted EPS outlook of at least $9.00. A clean third quarter with medical costs in check would support the recovery story.

What The Numbers Say

On this year's guidance, the stock looks expensive at around 44 times adjusted earnings. That's because 2026 is the trough year, hit by the lost bonus payments.

Cantor's math looks past it. The firm now models 2027 EPS of $17.96 and 2028 EPS of $28.27. On those estimates, the stock trades at about 22 times 2027 and about 14 times 2028 earnings. Its $460 target works out to roughly 16 times the 2028 number.

Bear Case 

What Could Break It

The ratings could disappoint. CMS made about half of the 2027 Star Ratings thresholds harder to reach, according to Healthcare Dive. A miss on top-quartile results would knock the 2028 earnings bridge out from under the stock.

Medical costs are the other risk. Utilization ran hotter than expected across the industry in 2025, and another spike in hospital, outpatient, or specialty drug costs would squeeze margins on a book that just grew fast.

The Valuation Risk

After a 50% run, a lot of good news is already in the price. The average Wall Street target sits only modestly above the current price, so Cantor is at the bullish end of the range.

Policy is a wildcard too. The next Medicare Advantage payment notice lands early next year, and Washington's appetite for cutting MA payments can change quickly.

How To Size It

Treat this as a starter position until you've seen the Star Ratings. If they confirm the recovery, add on any pullback ahead of the November 6 report.

If the ratings disappoint, step aside. A low-beta stock that misses its main catalyst can drift lower for months.

Quick Checklist 

✅ 2027 Star Ratings checked (share of members in 4-star-plus plans)
✅ Q3 earnings date confirmed (Friday, November 6, before the open)
✅ 2026 adjusted EPS outlook of at least $9.00 reaffirmed
✅ Position sized as a starter until the ratings are digested

Deep‑Dive Links

• Latest earnings report

• Analyst ratings and price targets

• Short interest data

• Company profile and investor relations

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha